Ahmad HA, Baker JF, Østergaard M, et al. - In the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) study, experts aspired to explore whether baseline MRI inflammation was associated with clinical response and remission. The study sample consisted of patients with early (≤ 2 years’ duration), anti-citrullinated peptide-positive methotrexate (MTX)-naïve rheumatoid arthritis (RA). Overall, 100/225 individuals had high baseline MRI inflammation. Remission rates were not significantly different with abatacept + MTX vs MTX in patients with low baseline MRI inflammation. In seropositive, early RA patients with MTX-naïve, presence of objectively measured high inflammation by MRI, showing poor prognosis, higher rates of remission with treatment with abatacept + MTX vs MTX.